Aqueous extract from Pepino (Solanum muricatumAit.) leaves ameliorated insulin resistance, hyperlipidemia, and hyperglycemia in mice with metabolic syndrome

doi:10.1111/jfbc.13518

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24376

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24376

题名:	Aqueous extract from Pepino (Solanum muricatumAit.) leaves ameliorated insulin resistance, hyperlipidemia, and hyperglycemia in mice with metabolic syndrome
作者:	Hsu, JY;Lin, HH;Wang, ZH;Chen, JH
关键词:	antioxidant effect;aqueous extract from pepino leaf;hyperglycemia;hyperlipidemia;insulin resistance
日期:	2020
上传时间:	2022-08-09T08:01:18Z (UTC)
出版者:	WILEY
ISSN:	0145-8884
摘要:	Solanum muricatum Ait. (Pepino) is a plant food commonly cultivated in the Penghu Island, Taiwan. This present study aimed to investigate the protective effects of aqueous extract of Pepino leaves (AEPL) in mice with metabolic syndrome. Metabolic syndrome animal model was induced by continuous high-fat diet feeding and low-dose streptozotocin (40 mg/ml) for 5 days. A 1% AEPL or metformin were given for 6 weeks after streptozotocin injection. The results revealed that 1% AEPL effectively reduced fasting blood glucose, insulin resistance, and hyperlipidemia in metabolic syndrome mice. Histologic examination revealed lipid accumulation in liver decreased by 1% AEPL treatment. Further, western blot analysis revealed 1% AEPL treatment managed enzymes related to lipid synthesis and oxidation pathways and hepatic glucose production. Besides, 1% AEPL treatment increased liver antioxidant activities to against oxidative stress. These results concluded that AEPL treatment attenuated insulin resistance, hyperlipidemia, and hyperglycemia of metabolic syndrome. Practical applications Metabolic syndrome (MS) is a multifactorial chronic disease which is characterized by dyslipidemia, insulin resistance, and hyperglycemia. However, there is no single drug or defined medication for MS so far. The present study revealed that AEPL treatment was able to regulate lipid metabolism and glycemic control at the molecular level to alleviate MS. AEPL has the potential to be a novo complementary medication for metabolic syndrome.
URI:	http://dx.doi.org/10.1111/jfbc.13518 https://www.webofscience.com/wos/woscc/full-record/WOS:000578696200001 https://ir.csmu.edu.tw:8080/handle/310902500/24376
關聯:	JOURNAL OF FOOD BIOCHEMISTRY ,2020 ,v44 ,issue 12
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	178	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....